Comparative Pharmacology
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
PROCALAMINE vs TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
None Documented
None Documented
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution